Feb 272017
 

By Talent4Boards Team

Talent4Boards - Great Talent builds Great Boards

– USA, MA – Arrakis Therapeutics, a pioneering biopharmaceutical company, has completed a $38 million Series A financing led by Canaan Partners with participation by Advent Life Sciences, Pfizer Inc., Celgene Corporation, Osage University Partners, and biotech industry leader Henri Termeer.… => Read more

Arrakis Therapeutics appoints Michael Gilman as Chairman and CEO along with raising $38m Series A financing led by Canaan Partners

From:: Arrakis Therapeutics appoints Michael Gilman as Chairman and CEO along with raising $38m Series A financing led by Canaan Partners

Sorry, the comment form is closed at this time.

%d bloggers like this: